SPONSORS
Alnylam is leading the translation of RNA interference into a whole class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, infectious and central nervous system and ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for treating a wide range of severe, debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA.
Alnylam has funded the scientific medical educational part of the meeting only.
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.
Alexion, AstraZeneca Rare Disease
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
BioPorto Diagnostics
When it comes to acute kidney injury (AKI), The NGAL Test™ helps you, “Know earlier. Manage better. With confidence.”
96% of healthcare professionals believe that early detection of AKI can lead to significantly better patient outcomes.1 The NGAL biomarker can help you identify patients at risk of AKI earlier. NGAL levels rise within 2 hours of kidney insult, up to 3 days before serum creatine can detect a change in kidney function2, providing you with a window of opportunity to appropriately intervene.
Visit Stand 29 to learn more about using The NGAL Test™ to identify and manage pediatric acute kidney injury (AKI). By providing an additional data point for assessing kidney damage, The NGAL Test can help you confidently make complex and potentially life-saving care decisions earlier.
We invite you to join Dr. David Selewski at the September 25th Industry Lunch Symposium to learn about using the NGAL biomarker in clinical practice with “Interesting Cases from the Bedside.”
Learn more about AKI, the NGAL biomarker, and The NGAL Test at www.bioporto.com.
1. Ipsos Mori UK Ltd. A Multidisciplinary and International Assessment of AKI Awareness. May 2022.
2. Devarajan, P. Biomark Med. 2010. Apr: 4(2): 265-280.
Chemo is part of the Spanish multinational Insud Pharma, a group with more than 45 years of history and 9000 professionals worldwide. Insud Pharma has a presence in all links of the chemical-pharmaceutical industry thanks to three synergistic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience). Our goal is to preserve and improve people’s health and well-being.
Chemo is a benchmark for the industry in research, development and manufacturing of a wide variety of active pharmaceutical ingredients (APIs) and a complete range of finished dosage forms (FDFs), both for human and veterinary use, for the main therapeutic areas.
We work to provide our partners with generic drugs of the highest standard, manufactured and packaged in our European facilities. We go hand in hand throughout the process, providing support in all aspects related to the complete product cycle (pharmaceutical development, registration, intellectual property, launch and logistical organization). Our spirit of customer service enables us to ensure strong relationships with our partners around the world. Service, innovation and quality make Chemo one of the most reliable generic suppliers in the B2B business.
State-of-the-art technology, high industrial capacity and vertical integration with our API plants mean that we control the processes from start to finish, making us a trusted partner for more than 1100 pharmaceutical companies in 96 countries.
Inmunova is an Argentine biotech company dedicated to researching and developing innovative medicines for rare infectious diseases lacking treatment options.
Our expertise lies in designing vaccines, therapeutic antibodies, and immunogens, encompassing the entire development process: from original concept and proof-of-concept studies to preclinical and clinical phases, registration procedures, and pharmacovigilance.
We are part of Insud, a globally diversified company operating in over 40 countries, with a significant presence in the pharmaceutical industry.
Currently, we are entering the final stage of research for the world’s first treatment for hemolytic uremic syndrome (HUS). The clinical development programme has been endorsed by the Food and Drug Administration (FDA), and the European Medicines Agency (EMA), receiving Orphan Drug designation in both Europe and the United States, as well as Rare Pediatric Disease Designation in the US.
At Inmunova, our priority is to generate treatment options using high global standards of quality and best practices for product research and development. Innovation and scientific solidity are the cornerstones of our work.
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
At Recordati Rare Diseases, we focus on the few – those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions.
Samsung Bioepis is a biopharmaceutical company dedicated to optimizing access to biologic medicines by bringing biosimilars to patients who need them.
At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised biopharmaceutical company, we provide sustainable medicines to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a rare expertise and a strength in access that allows us to be a partner in care for those with high unmet needs. Sobi headquarters are located in Stockholm, Sweden.
Advicenne is dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults.
We are dedicated to improving patients’ daily health and life and are committed to tackle the challenge of high unmet medical needs.
Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) has received its Marketing Approval for distal renal tubular acidosis (dRTA) in EU and GB. Sibnayal® is approved for both the genetic and acquired form of dRTA. For more information, visit www.advicenne.com.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease through the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 54,400 people in 80 countries, of which 3,300 work with rare diseases.
Avanzanite Bioscience is a commercial-stage specialty pharmaceutical company, whose sole mission is to ensure novel medicines reach patients suffering from rare diseases in every market across Europe.
Derived from the word “Tanzanite” – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian.
The economic goal is to enter commercial and/or development partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets and beyond; this is a unique expertise and core competency of the experienced Avanzanite team through its decades of navigating this area.
Many of these biotechs develop breakthrough Orphan Drugs, however they often do not reach patients in need which is a shame and unfair.
Equally important, the Company’s humanitarian goal stems from our commitment to enabling access mostly to novel or even already commercialised medicines, for patients who suffer from orphan diseases, regardless of where they live in Europe.
Avanzanite acquires, licenses or distributes approved or late-stage medicines for rare diseases and commercialises them everywhere in Europe (and beyond), even when nobody else will.
Avanzanite’s founding mission is to tackle these critical issues in the European orphan drug space and beyond, with our unique business model since we believe patients with Rare Diseases should have access to the latest medical innovations regardless of where they live.
Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.
For more information, go to www.bayer.com.
Fresenius Medical Care is the world’s leading provider of products and services for people with kidney diseases, of whom approximately 4.1 million patients worldwide receive regular dialysis treatment. Through its network of 3,862 dialysis centers, Fresenius Medical Care provides dialysis treatment for approximately 325,000 patients worldwide and is the leading provider of dialysis products such as dialysis machines and dialyzers.
Immundiagnostik AG is an internationally active diagnostics company developing and manufacturing innovative immunoassays and other analytical methods for routine and research. Immundiagnostik provides novel immunoassays and analytical tools focused on gastroenterology, nutrition, cardiovascular and renal diseases, bone metabolism, clinical immunology, oncology and more. We also offer laboratory support services, including proficiency testing, custom bulk packaging, and validation assistance. Visit Immundiagnostik to discover more about our products, services, and brands.
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Food for Special Medical Purposes: Made in Germany – Available Worldwide
metaX, founded in 1999, is an independent German family business. We work with prestigious universities and special hospitals, research laboratories, and competent business partners in Germany and worldwide. We are a team of highly motivated professionals dedicated to working creatively on innovations in nephrological and metabolic dietetics. metaX offers dietetic Food for Special Medical Purposes: Products for the dietetic management of Chronic Renal Failure, Protein Supplements for inborn errors of metabolism, a wide range of Low Protein Products, Supplements for Food Fortification, and Micronutrient Supplements.
Certified Quality – Service to Our Customers
metaX develops and manufactures almost all their products themselves. metaX is a company certified according to HACCP and ISO 9001:2015. State-controlled production facilities, many years of experience, sound knowledge, and highest quality demands provide excellent product quality. Our products are analyzed and monitored by accredited laboratories – service to our customers, without compromise.
metaX services include brochures, recipes, cooking classes, patient holiday activities, and medical symposia for professionals.
Dedicated to the Health and Wellbeing of People
At metaX, we are unwaveringly dedicated to the health and wellbeing of people. This commitment is at the core of everything we do. The symbol “X” in the metaX company logo represents a human being. It symbolizes that metaX is dedicated to the well-being and health of people. The personal interaction with the people for whom our products are developed is very close to our hearts. We look forward to hearing from you!
At Mozarc Medical, we use technology and expertise to change the treatment of kidney disease. Empowering providers with a holistic, comprehensive portfolio. Providing caregivers with unwavering support. And always putting the patient first.
Sponsorship Opportunities
The 56th Annual Scientific Meeting of the European Society for Paediatric Nephrology (ESPN) which will be held in Valencia from 23 to 27 September 2024, offers our industry partners several opportunities to reach a wide international audience working in the field of Paediatric Nephrology.
Starting from 2024, we have the pleasure to give to Companies the additional great chance to become an ESPN CORPORATE PARTNER, with a powerful commitment as significant associate for the Society and the Annual Meeting.
We also maintained a broad spectrum of sponsorship opportunities reserved exclusively to the Annual Meeting, for those sponsors which prefer to support only the Congress.
For more information on Sponsors & Exhibitors opportunity, please contact Sponsor& Exhibitor Department sponsorESPN@oic.it.
OIC Srl
Viale Giovine Italia, 17
50122 Florence – Italy
Tel. +39 055 50351
Fax +39 055 5001912
E-mail sponsorESPN@oic.it